PROLIA (DENOSUMAB) V LEChENII POSTMENOPAUZAL'NOGO OSTEOPOROZA:ANALIZ POSLEDNIKh PUBLIKATsIY

1. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellström D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S. The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension. J Clin Endocrinol Metab. 2013 Aug 26. [Epub ahead of print].

2. McClung MR, Lewiecki EM, Geller Ml, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013 Jan;24(1):227—35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.

3. Genant HK, Libanati C, Engelke K, Zanchetta JR, Höiseth A, Yuen CK, Stonkus S, Bolognese MA, Franek E, Fuerst T, Radcliffe HS, McClung MR. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 2013 Oct;56(2):48238. doi: 10.1016/j.bone.2013.07.011. Epub 2013 Jul 17.

4. Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, Minakuchi K. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013 Aug 9. [Epub ahead of print].

5. Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US. Appl Health Econ Health Policy. 2013 Jul 19. [Epub ahead of print].